Stocks
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -233.8% | -235.5% | -810.4% | -853.2% | -1 395% | -907.8% | ||
| Changes by years, y/y, % | +65pp | -2pp | -575pp | -43pp | -542pp | +36.1% | |||
Intellia Therapeutics. EBITDA margin, %
Intellia Therapeutics. EBITDA margin, changes, pp
Intellia Therapeutics (NTLA) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
| EBITDA margin, % | ? | -887.3% | -973.5% | -1 093% | -7 169% | -385.3% | -907.8% | |
| Changes by years, y/y, % | +375pp | -272pp | -371pp | -6 398pp | +502pp | |||
| Changes by quarters, q/q, % | -116pp | -86pp | -120pp | -6 076pp | +6 783pp | |||
